Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-17
2009-11-03
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
07612106
ABSTRACT:
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor.Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
REFERENCES:
patent: 7241792 (2007-07-01), Boatman et al.
patent: 2006/0167270 (2006-07-01), Semple et al.
patent: 10148617 (2003-04-01), None
patent: 0529854 (1993-03-01), None
patent: 1305286 (2004-12-01), None
patent: WO 0166520 (2001-09-01), None
patent: WO 0179169 (2001-10-01), None
patent: WO 02094830 (2002-11-01), None
patent: WO 03002582 (2003-01-01), None
patent: WO 03022814 (2003-03-01), None
patent: WO 03062200 (2003-07-01), None
patent: WO 03078409 (2003-09-01), None
patent: WO 2004032928 (2004-04-01), None
patent: WO 2004033431 (2004-04-01), None
patent: WO 2004103370 (2004-12-01), None
patent: WO 2005011677 (2005-02-01), None
patent: WO 2005016867 (2005-02-01), None
patent: WO 2005016870 (2005-02-01), None
patent: WO 2005044816 (2005-05-01), None
patent: WO 2005077950 (2005-08-01), None
Delporte, M., et al, “Pre and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies”, Biochem. J. (2002) 367, pp. 677-685.
Karpe, F., et al, “The nicotinic acid receptor—a new mechanism for an old drug”, The Lancet, vol. 363, Jun. 5, 2004, pp. 1892-1894.
Kubota, N., et al, “Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation”, The Journal of Biological Chemistry, vol. 277, No. 29, Jul. 19, 2002, pp. 25863-25866.
Li, J., et al, “Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits”, Dept. of Cardiovasology, Second Xiangya Hospital, Central South University, Changsha, China, pp. 480-484 .
Okamoto, Y., et al, “Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice”, Circulation-Journal of the American Heart Association, Nov. 26, 2002, pp. 2767-2770, [retrieved from the Internet on Apr. 24, 2008] http://www.circ.ahajournals.org.
Tunaru, S., et al, “PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect”, Nature Medicine, Mar. 2003, vol. 9, pp. 352-355 (with “Supplementary Methods” included, one page).
Zhang, et al, “Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A”, Biochemical and Biophysical Research Communications, (2005) 334, pp. 729-732.
Carballo-Jane et al., “Comparison of rat and dog models of vasodilation and lipolysis for the calculation of a therapeutic index for GPR109A agonists,”Journal of Pharmacological and Toxicological Methods, Article in Press, doi:10.1016/j.vascn.2007.05.007 (2007).
Carballo-Jane et al., “Comparison of rat and dog models of vasodilation and lipolysis for the calculation of a therapeutic index for GPRI09A agonists,”Journal of Pharmacological and Toxicological Methods, 56(3). pp. 308-316, (2007).
Gharbaoui et al., “Agonist lead identification for the high affinity niacin receptor GPR109a ,”Bioorganic & Medicinal Chemistry Letters, 17:4914-4919 (2007).
Jung et al., “Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b,”Journal of Medicinal Chemistry, 50:1445-1448 (2007).
Maciejewski-Lenoir et al., “Langerhans cells release prostaglandin D2in response to nicotinic acid,”Journal of Investigative Dermatology, 126:2637-2646 (2006).
Semple et al., “Recent progress in the discovery of niacin receptor agonists,”Current Opinion in Drug Discovery & Development, 10:452-459, (2007).
Semple et al., “1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b,”Journal of Medicinal Chemistry49:1227-1230, (2006).
Semple, “Niacin receptor agonists,”Presentation, American Chemical Society 233rdNational Meeting & Exposition, Mar. 25, 2007 —Mar. 29, 2007, Chicago, Illinois.
Semple, “Discovery of selective agonists for GPRI09a and GPR109b, the high and low affinity receptors for niacin,”Presentation,GPCRs in Medicinal Chemistry, jointly organized by the Society Of Chemical Industry, Royal Society of Chemistry and the Societa Chimica Italiana, Sep. 18, 2006 —Sep. 20, 2006, Verona, Italy.
Skinner et al, “Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a,”Poster, 30thNational Medicinal Chemistry Symposium, Jun. 25, 2006 —Jun. 29, 2006, Seattle, WA.
Taggart et al., “(D)-62-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G,”The Journal of Biological Chemistry, 280:26649-26652, (2005).
Alterman, M. et al., “Fast microwave-assisted preparation of aryl and vinyl nitriles and the corresponding tetrazoles from organo-halides”, J. Org. Chem. 65:7984-89 (2000)(supporting information attached).
Bays, H. et al., “Pharmacotherapy for Dyslipidaemia —Current therapies and future agents”, Expert Opinion on Pharmacotherapy, Ashley, London, GB, vol. 4(11):1901-38 (2003).
Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987*.
Cahn, R.S. et al., “Specification of molecular chirality”, Angew. Chem. Internat. Edit. 5(4):385-415 (1966).
Chang, A.Y. et al., “Ciglitazone, a new hypoglycemic agent”, Diabetes 32:830-38 (1983).
Clayton, S. et al., “A total synthesis of (±)-epibatidine”, Tetrahedron Letters 34(46):7493-6 (1993).
Cohen, T. et al., “Synthetically useful β-lithioalkoxides from reductive lithiation of epoxides by aromatic radical anions”, J. Org. Chem. 55:1528-36 (1990).
Coleman, D.L., “Fat(fat) and Tubby (tub): Two autosomal recessive mutations causing obesity syndromes in the mouse”, Journal of Heredity 81:424-7 (1990).
Coleman, Douglas L., “Diabetes-obesity syndromes in mice”, Diabetes 31:1-6 (1982).
Collier, T. L. et al., “Radiosynthesis and in-vivo evaluation of the psuedopeptide s-opioid antagonist”, J. Labelled Cpd. Radiopharm. 42(1):S264-6 (1999).
Cornhill, J. Frederick et al., “Topographic study of sudanophilic lesions in cholesterol-fed minipigs by image analysis”, Arteriosclerosis Thrombosis, and Vascular Biology 5(5):415-426 (1985).
Corsaro, A. et al., “Steric course of some cyclopropanation reactions of L-threo-hex-4- enopyranosides”, Tetrahedron Letters 60:3787-95 (2004).
Delporte, Marie-Laure et al., “Pre- and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies”, Biochem. J. 367:677-85 (2002).
Effenberger, F. et al., “Regioselective halo- and carbodesilylation of (trimethylsily1)-1-methylpyrazoles”, J. Org. Chem. 49:4687-95 (1984).
Eriksson et al., “Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy”, Diabetes 31:1-6 (1982).
Flechtner-Mors, M.
Boatman P. Douglas
Jung Jae-Kyu
Schrader Thomas O.
Semple Graeme
Skinner Philip J.
Arena Pharmaceuticals Inc.
Fish & Richardson P.C.
Saeed Kamal A
Spruce Lyle W.
LandOfFree
Fused pyrazole derivatives and methods of treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused pyrazole derivatives and methods of treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused pyrazole derivatives and methods of treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079849